Utang jangka cendhak marang modal Aeterna Zentaris (CSCI)

This chart of the current market value of COSCIENS Biopharma Inc. (CSCI) reflects a debt-to-equity ratio of 0.05. The company is currently integrating an acquired private biotech firm, temporarily pausing mergers to focus on developing its own endocrine research. The Canadian enterprise relies on unique patents and global distribution channels, while demand for its therapies remains constant regardless of market cycles.

For the COSCIENS Biopharma Inc. (CSCI) biopharmaceutical ecosystem, which is developing the commercialization of orphan drugs, the company's short-term leverage history visualizes the balance between debt capital and equity. This ratio compares liabilities with a maturity of more than one year to total capital, allowing investors to assess financial stability and the risk of excessive debt load while scaling the proprietary Macrilen molecules.